NCT05170828 2026-02-24
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
Ossium Health, Inc.
Phase 1 Withdrawn
Clinical Trials
27 trialsNCT06522373 2026-02-24
Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT05248685 2025-06-11
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Beijing Boren Hospital
Phase 1 Withdrawn
NCT04556266 2025-05-13
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT05266950 2024-11-14
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Beijing Boren Hospital
Phase 1 Withdrawn
NCT05487495 2024-11-14
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Beijing Boren Hospital
Phase 1 Withdrawn
NCT05375253 2024-09-03
Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies
University of Nebraska
Phase 1 Withdrawn
NCT04955938 2024-07-31
A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
University of Chicago
Phase 1 Withdrawn
NCT05321940 2023-12-04
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
University of Miami
Phase 1 Withdrawn
NCT02786485 2020-10-05
Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT
Bellicum Pharmaceuticals
Phase 1 Withdrawn
NCT00004114 2020-07-31
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT02274506 2020-01-22
Infusion of Allogeneic, 3rd Party CD19-specific T Cells
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02905994 2018-05-04
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
Massachusetts General Hospital
Phase 1 Withdrawn
NCT02194374 2017-06-12
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02640833 2016-07-26
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
AbbVie
Phase 1 Withdrawn
NCT00002956 2016-03-21
Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT02556346 2016-03-02
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Molecular Templates, Inc.
Phase 1 Withdrawn
NCT01336478 2015-06-08
CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation
Imperial College London
Phase 1 Withdrawn
NCT00024115 2015-04-28
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT01065545 2015-04-10
The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia
Northwestern University
Phase 1 Withdrawn
NCT00458744 2014-08-08
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
Children's Oncology Group
Phase 1 Withdrawn
NCT01478074 2014-01-03
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
Altor BioScience
Phase 1 Withdrawn
NCT00957320 2013-12-03
Study of Sirolimus With PEG-Asparaginase in Acute Lymphoblastic Leukemia (ALL)
Emory University
Phase 1 Withdrawn
NCT00968461 2013-04-15
Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00003435 2013-03-07
Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer
Duke University
Phase 1 Withdrawn
NCT00972101 2012-10-11
Infusion of Expanded Cord Blood T Cells
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00886496 2012-06-20
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia
Enzon Pharmaceuticals, Inc.
Phase 1 Withdrawn